臨床検査51巻5号

2007年05月発行

今月の主題 脂質 脂質代謝異常と疾病

ステロイドホルモンと生活習慣病

著者： 柳瀬敏彦¹

所属機関： ¹九州大学大学院医学研究院病態制御内科

ページ範囲：P.515 - P.522

　脂質，代謝系に影響を与えるステロイドホルモンとして，糖質コルチコイド(GC)，性ステロイド(テストステロン，エストロゲン)を取り上げ，概説した．GCは，ヒトではその過剰症が副作用としての高脂血症，糖尿病の発症につながる．一方，性ステロイドには抗肥満作用があり，加齢に伴う性ステロイドの低下は生活習慣病，特に内臓脂肪型肥満を基盤とするメタボリックシンドロームの発症の重要な背景要因となっている可能性がある．〔臨床検査　51：515-522，2007〕

参考文献

1) 柳瀬敏彦，名和田新：合成グルココルチコイド．日本臨牀 52：578-582, 1994

2) 柳瀬敏彦，名和田新：ステロイドホルモンの動脈硬化促進作用．内分泌・糖尿病 4：545-552, 1997

3) 白井厚治：ステロイド治療と血清脂質．医学のあゆみ 168：960-963, 1994

4) Aoki K, Kawai S：Glucocorticoid therapy decreases serum lipoprotein(a)concentration in rheumatic disease. Int Med 32：382-386, 1993

5) Naito M, Yasue M, Asai K, et al：Effects of dexamethasone on experimental atherosclerosis in cholesterol-fed rabbits. J Nutr Sci Vitaminol 38：255-264, 1992

6) Saito A, Sheppard KE, Fullerton J, et al：Glucocorticoid receptor expression is down-regulated by Lp(a)lipoprotein in vascular smooth muscle cells. Endocrinology 138：3707-3713, 1995

7) 柳瀬敏彦：内分泌・膵疾患による糖尿病．糖尿病学の進歩2004(日本糖尿病学会編)，診断と治療社，pp14-21, 2005

8) Bernal-Mizrachi C, Weng S, Feng C, et al：Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice. Nat Med 9：1069-1075, 2003

9) Masuzaki H, Paterson J, Shinyama H, et al：A transgenic model of visceral obesity and the metabolic syndrome. Science 294：2166-2170, 2001

10) Tauchmanova L, Rossi R, Biondi B, et al：Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87：4872-4878, 2002

11) Liu PY, Death AK, Handelsman DJ：Androgens and cardiovascular disease. Endocrine Rev 24：313-340, 2003

12) Ding EL, Song Y, Malic VS, et al：Sex differences of endogeneous sex hormones and risk of type 2 diabetes. A systemic Review and Meta-analysis. JAMA 295：1288-1299, 2006

13) Kyle UG, Genton L, Hans D, et al：Age-related difference in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr 55：663-672, 2001

14) Synder PJ, Peachery H, Berlin JA, et al：Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 65：2670-2677, 2000

15) Mauras N, Hayes V, Welch S, et al：Testosterone deficiency in young men：marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 83：1886-1992, 1998

16) Page ST, Herbst KL, Amory JK, et al：Testosterone administration suppresses adiponectin levels in men. J Androl 26：85-92, 2005

17) Sato T, Matsumoto T, Yamada T, et al：Late onset of obesity in male androgen receptor-deficient(AR KO)mice. Biochem Biophys Res Commun 300：167-171, 2003

18) Fan W, Yanase T, Nomura M, et al：Androgen receptor null malemice develop late-onset obesity due to decreased energy expenditure and lypolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54：1000-1008, 2005

19) Nishizawa H, Shimomura I, Kishida K, et al：Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51：2734-2741, 2002

20) Lin HY, Xu Q, Yeh S, et al：Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 54：1717-1725, 2005

21) 柳瀬敏彦，名和田新：エストロゲンと動脈硬化．現代医療 97：2565-2570, 1997

22) Grodstein F, Stampfer MJ, Mason JE, et al：Post menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335：453-461, 1996

23) Grandy D, Herrington D, Bittner V, et al：Cardiovascular disease outcome during 6.8 years hormone therapy. JAMA 288：49-57, 2002

24) Writing Group for the women's Health Initiative Investigators：Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288：321-333, 2002

25) Lobe EA：Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73：925-930, 1991

26) Barrett-Connor E, Grady D, Sashegyi A, et al：Raloxifene and cardiovascular events in osteoporotic postmenopausal women：four-year results from the MORE(Multiple Outcomes of Raloxifene Evaluation)randomized trial. JAMA 287：847-857, 2002

27) Lasco A, Gaudio A, Morabito N, et al：Effects of a lomg-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Diabetologia 47：571-574, 2004

28) Crook D, Godsland IF, Hull J, et al：Hormone replacement therapy with dydrogesterone and 17β-oestradiol；Effects on serum lipoprotein and glucose tolerance during 24-month follow-up. Br J Obstet Gynaecol 104：298-304, 1997

29) Morishima A, Grumbach MM, Simpson ER, et al：Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80：3689-3698, 1995

30) Carani C, Qin K, Simoni M, et al：Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337：91-95, 1997

31) Bilezikian JP, Morishima A, Bell J, et al：Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339：599-603, 1998

32) Conte FA, Grumbach MM, Ito Y, et al：A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase(P450arom). J Clin Endocrinol Metab 78：1287-1292, 1994

33) Herrmann BL, Saller B, Janssen OE, et al：Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 87：5476-5484, 2002

34) Smith EP, Boyd J, Frank GR, et al：Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331：1056-1061, 1994

35) Heine PA, Taylor JA, Iwamoto GA, et al：Increased adipose tissue in male and female estrogen alpha knockout mice. Proc Natl Acad Sci USA 97：12729-12734, 2000

36) Couse JF, Korach KS：Estrogen receptor null mice：what have we learned and where will they lead? Endocrine Review 20：358-417, 1999

37) Jones MEE, Thorburn AW, Britt KL, et al：Aromatase deficient(ArKO)mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA 97：12735-12740, 2000

38) Misso M, Murata Y, Boon WC, et al：Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinol 144：1474-1480, 2003

39) Takeda K, Toda K, Saibara T, et al：Progressive development of insulin resistance phenotype in male mice with complete aromatase(CYP19)deficiency. J Endocrinol 176：237-246, 2003

40) Nemoto Y, Toda K, Ono M, et al：Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clinical Investigation 105：1819-1825, 2000